Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139491 | 0.87 | HTR2A (0.45) | CHRNA7SLC5A1SLC5A2HTR2AHTR2C | |
| SCHEMBL20141555 | 0.86 | HTR2A (0.44) | CHRNA7SLC5A1SLC5A2PTPN1HTR2A | |
| SCHEMBL20140091 | 0.85 | SLC5A1 (0.42) | CHRNA7SLC5A1SLC5A2HTR2AHTR2C | |
| SCHEMBL20139495 | 0.85 | HTR2A (0.42) | CHRNA7SLC5A1SLC5A2HTR2AHTR2C | |
| SCHEMBL20139395 | 0.84 | HTR2A (0.39) | CHRNA7SLC5A1SLC5A2PTPN1HTR2A | |
| SCHEMBL20140059 | 0.84 | HTR2A (0.43) | CHRNA7PTPN1HTR2AHTR2CMEN1 | |
| SCHEMBL21557886 | 0.83 | SLC5A1 (0.47) | CHRNA7SLC5A1SLC5A2PTPN1HTR2A | |
| SCHEMBL20139432 | 0.82 | HTR2A (0.45) | CHRNA7SLC5A1SLC5A2HTR2AHTR2C | |
| SCHEMBL20139443 | 0.81 | RAB9A (0.48) | CHRNA7PTPN1HTR2AHTR2CHRH3 | |
| SCHEMBL23700112 | 0.81 | MAOB (0.49) | SLC5A1SLC5A2PTPN1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | CHRNA7 3628/4885SLC5A1 2/4885SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.